Page 176 - NobleCon20-Book-Project

Health Care
Date November 18, 2024 Health Care
52wk High $1.82
52wk Low $0.20 Unicycive Therapeutics, Inc. UNCY $0.46
4300 El Camino Real
Los Altos, CA 94022

(USD - in millions) unicycive.com
Market Cap 46.5
Enterprise 15.0
Basic Shares Out. 103.80 COMPANY OVERVIEW
Float 55.87
Institutional Holdings 15.15% Detailed Analysis:Channelchek.com
Short Interest 1.05
Avg. 90-Day Volume 1.81 Unicycive Therapeutics is a biotechnology company developing novel
treatments for kidney diseases. Unicycive’s lead drug candidate,
oxylanthanum carbonate (OLC), is a novel investigational phosphate
binding agent being developed for the treatment of hyperphosphatemia
EPS Data in chronic kidney disease patients on dialysis. Positive pivotal trial
results were reported in June 2024 for OLC, and a New Drug
2022 2023 2024 Application (NDA) is under review by the U.S. Food and Drug
CQ1 (0.24) (0.97) (0.61) Administration (FDA) with a Prescription Drug User Fee Act (PDUFA)
CQ2 (0.24) (0.29) 0.15 Target Action Date of June 28, 2025.

CQ3 (0.37) (0.13) (0.05)
CQ4 (0.35) (0.16) (0.08)
CY (1.20) (1.28) (0.62) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.28
ROE (ttm) -147.05
Debt-to-Total Cap. (mrq) 2.82
Fiscal Year End 31-Dec
4300 El Camin Los Altos CA 94022

Key Executives
CEO: Gupta, Shalabh
CFO: Townsend, John
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures